FibroBiologics Announces Preliminary Proof Of Concept For Fibroblast-Based Diabetes Treatment
FibroBiologics Announces Preliminary Proof Of Concept For Fibroblast-Based Diabetes Treatment
FibroBiologics, Inc., (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the progress of a clinical program under development using a fibroblast-based pancreatic beta cell spheroid that secretes insulin in vitro upon glucose stimulation. The development and reproducibility of this work demonstrates that an organoid composed of fibroblasts, beta cells and other components can successfully and durably secrete insulin.
Fibrobiologics, Inc.（納斯達克股票代碼：FBLG）（“Fibrobiologics”）是一家臨床階段的生物技術公司，擁有150多項已頒發和正在申請的專利，專注於使用成纖維細胞和成纖維細胞衍生材料開發慢性病的療法和潛在的治療方法。該公司宣佈了一項正在開發的使用分泌胰島素的成纖維細胞胰腺β細胞球體的臨床項目的進展 體外 在葡萄糖刺激下。這項研究的發展和可重複性表明，由成纖維細胞、β細胞和其他成分組成的類器官可以成功而持久地分泌胰島素。
"This early proof of concept is encouraging and may lead to a new and durable potential allogeneic treatment option for people with insulin-dependent diabetes," said Hamid Khoja, Ph.D., Chief Scientific Officer. "We look forward to confirming these early results and in vivo utility. We will then determine whether to designate the program as an early phase pre-clinical project for developing a minimally invasive therapeutic for type 1 diabetes."
首席科學官哈米德·霍賈博士說：“這種早期的概念驗證令人鼓舞，可能會爲胰島素依賴型糖尿病患者提供一種新的、持久的潛在異基因治療選擇。”“我們期待確認這些早期結果， 在活體中 效用。然後，我們將決定是否將該項目指定爲開發1型糖尿病微創療法的早期臨床前項目。”
譯文內容由第三人軟體翻譯。